Ke hōʻike nei ʻo RegeneRx Biopharmaceuticals, Inc. ua hōʻike ka poʻe noiʻi i ka maikaʻi therapeutic o Thymosin Beta 4 (Tβ4) ma ke ʻano he lāʻau lapaʻau e kūʻē i ka hyperglycemia (diabetic) -i hoʻololi ʻia i nā cell epithelial corneal kanaka.
"Ua wehewehe kā mākou noiʻi no ka manawa mua he hana koʻikoʻi ka Tβ4 a me ka vasoactive intestinal peptide (VIP) combo treatment i ka hoʻoponopono ʻana i ka paʻa paʻa paʻa a me ka hoʻonohonoho hou ʻana o ka cytoskeleton [o ka cornea], kahi pili pili i ka paʻa paʻa. Eia kekahi, ua hoʻokūpaʻa ikaika ʻo Tβ4 i kāna hana ma ke ʻano he lāʻau hoʻohui no ka maʻi maʻi maʻi me ka ʻole o nā hopena ʻaoʻao, a laila e hōʻoluʻolu i nā hemahema o nā ʻano o ka mālama ʻana i kēia manawa, "e like me ka hui noiʻi.
Ua hōʻike ʻia ka noiʻi ma ka hui ʻo Association for Research in Vision and Ophthalmology (ARVO) 2022, i mālama ʻia ma Mei 1-4, 2022, ma Denver, Colorado. Ua komo ka hui noiʻi i nā ʻepekema a me nā kauka mai Wayne State University School of Medicine ma Detroit, MI; ke Kulanui o Central Florida College of Health Professors and Sciences ma Orlando, FL; a me ke Kulanui ʻo Mansoura ma Mansoura, ʻAigupita. Ua kākoʻo kālā ʻia ka noiʻi e ka National Institutes of Health, ka Eversight Center for Vision and Eye Banking Research, a me Research to Prevent Blindness.
He aha e lawe ʻia mai kēia ʻatikala:
- “Our study elucidates for the first time that a Tβ4 and vasoactive intestinal peptide (VIP) combo treatment plays a crucial role in regulating the tight junction stability and cytoskeleton rearrangement [of the cornea], which are closely related to barrier integrity.
- The research was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 meeting, held May 1-4, 2022, in Denver, Colorado.
- is reporting that researchers have demonstrated the therapeutic efficacy of Thymosin Beta 4 (Tβ4) as a combination treatment against hyperglycemia (diabetic)-induced changes in human corneal epithelial cells.
